Finally, whereas controversial data are available about the potential benefit of GLP-1 RAs and DDP-4Is in AMI patients with previous or developing HF [250,251,252,253,254,255], dapagliflozin consistently reduced the composite endpoint of CV death or hospitalizations for HF in this population [249]. The gene discussed is GLP1R; the disease is hydrops fetalis.